Electrocardiography

Global Cardiovascular Devices Market to 2026 - Featuring Abbott Laboratories, Biotronik & Getinge Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 14, 2020
Health, Cardiology, Cardiac electrophysiology, Branches of biology, Medicine, Clinical medicine, Cardiac monitoring, Electrocardiography, Monitoring, Biotronik, Clinical cardiac electrophysiology

The global cardiovascular devices market is projected to witness considerable growth during the forecast period.

Key Points: 
  • The global cardiovascular devices market is projected to witness considerable growth during the forecast period.
  • The cardiovascular devices market is bifurcated on the basis of type of devices into diagnostic and monitoring devices and surgical devices.
  • The cardiovascular devices market based on diagnostic and monitoring devices is further segmented into MRI, electrocardiogram (ECG), remote cardiac monitoring, cardiac CT, and others.
  • Whereas the cardiovascular devices market based on surgical devices is further segmented into stents, catheters, cardiac assist devices, cardiac rhythm management device, and others.

Analysis on Impact of COVID-19- Global Cardiology Electrodes Market 2020-2024 | Evolving Opportunities with 3M Co. and ADInstruments Pty Ltd. | Technavio

Retrieved on: 
Thursday, August 13, 2020
Health, Cardiology, Branches of biology, Medicine, Physiology, Electrophysiology, Cardiac electrophysiology, Electrodiagnosis, Electrocardiography, Lithium-ion battery, Electrode

The global cardiology electrodes market size is expected to grow by USD 55.43 million as per Technavio.

Key Points: 
  • The global cardiology electrodes market size is expected to grow by USD 55.43 million as per Technavio.
  • View the full release here: https://www.businesswire.com/news/home/20200813005430/en/
    Technavio has announced its latest market research report titled Global Cardiology Electrodes Market 2020-2024 (Graphic: Business Wire)
    Read the 120-page report with TOC on "Cardiology Electrodes Market Analysis Report by Product (Resting ECG electrodes, Short-term monitoring ECG electrodes, Long-term monitoring ECG electrodes, Stress test ECG electrodes, and Neonatal ECG electrodes) and Geography (Europe, North America, APAC, South America, and MEA), and the Segment Forecasts, 2020-2024".
  • In addition, the increasing demand for disposable electrodes is anticipated to boost the growth of the cardiology electrodes market.
  • Dry contact electrodes and dry noncontact electrodes have been developed to overcome the limitations of traditional wet Ag/AgCl electrodes.

Cardiac Monitoring Market To Reach USD 26.83 Billion By 2027 | CAGR:3.9% | Reports And Data

Retrieved on: 
Monday, July 27, 2020
Branches of biology, Medicine, Cardiac electrophysiology, Clinical medicine, Cardiac monitoring, Medical monitoring, Monitoring, Medicare, Electrocardiography

Cardiac monitoring, also referred to as continuous or intermittent monitoring, concerns the monitoring of the activity of the heart, which is generally examined using ECG.

Key Points: 
  • Cardiac monitoring, also referred to as continuous or intermittent monitoring, concerns the monitoring of the activity of the heart, which is generally examined using ECG.
  • In addition to larger target population favorable reimbursement policies is major factor driving the cardiac monitoring market share.
  • Insurance companies like Medicare cover cardiac monitoring for inpatient, outpatient as well as ambulatory for Holter, event or patch type monitoring and for implantable devices in the cardiac monitoring market.
  • For the purpose of this report, Reports and Data has segmented the Cardiac monitoring market on the basis of types, end use and region:
    Type Outlook (Revenue in Million USD; 20172027)

BioSig Technologies, Inc. Adopts Stockholder Rights Agreement

Retrieved on: 
Thursday, July 16, 2020
Medicine, Branches of biology, Clinical medicine, Cardiac electrophysiology, Electrocardiography, Electrodiagnosis, Electrophysiology

BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its Board of Directors had adopted a stockholder Rights Agreement (the Rights Agreement).

Key Points: 
  • BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its Board of Directors had adopted a stockholder Rights Agreement (the Rights Agreement).
  • The Rights Agreement applies equally to all current and future stockholders.
  • The Rights Agreement has a duration of one year, expiring July 13, 2021, and is similar to those adopted by many other public companies.
  • This announcement is a summary only and is qualified by reference to the full text of the Rights Agreement.

VectraCor and GS GmbH (Corpuls) Form Licensing Agreement to Incorporate VectraCor's 22-Lead ECG and CEB® (Cardiac Electrical Biomarker) Technology in Corpuls Defibrillators

Retrieved on: 
Thursday, July 16, 2020
Medicine, Branches of biology, Cardiac electrophysiology, Clinical medicine, Defibrillation, Electrocardiography, Medical device, Emergency department

VectraCor currently has this technologyintegrated into their VectraplexECG System, used mainly in Emergency Departments, Urgent Cares andDoctor's Offices.

Key Points: 
  • VectraCor currently has this technologyintegrated into their VectraplexECG System, used mainly in Emergency Departments, Urgent Cares andDoctor's Offices.
  • The VectraplexECG System has approval in the United States (FDA), Europe (CE Mark),Taiwan and Australia and is patented worldwide.
  • Dr. Christian Klimmer, CEO of corpuls said, "In 1991 corpuls was the first medical device company in the fieldof multi-parameter / defibrillators introducing the 12-lead ECG to the market.
  • With the introduction of the 22-lead ECG and the CEB together withVectraCor we will again set the new standard in diagnosing cardiovascular disease, in particular in EMS.

VectraCor and GS GmbH (Corpuls) Form Licensing Agreement to Incorporate VectraCor's 22-Lead ECG and CEB® (Cardiac Electrical Biomarker) Technology in Corpuls Defibrillators

Retrieved on: 
Thursday, July 16, 2020
Medicine, Branches of biology, Cardiac electrophysiology, Clinical medicine, Defibrillation, Electrocardiography, Medical device, Emergency department

VectraCor currently has this technologyintegrated into their VectraplexECG System, used mainly in Emergency Departments, Urgent Cares andDoctor's Offices.

Key Points: 
  • VectraCor currently has this technologyintegrated into their VectraplexECG System, used mainly in Emergency Departments, Urgent Cares andDoctor's Offices.
  • The VectraplexECG System has approval in the United States (FDA), Europe (CE Mark),Taiwan and Australia and is patented worldwide.
  • Dr. Christian Klimmer, CEO of corpuls said, "In 1991 corpuls was the first medical device company in the fieldof multi-parameter / defibrillators introducing the 12-lead ECG to the market.
  • With the introduction of the 22-lead ECG and the CEB together withVectraCor we will again set the new standard in diagnosing cardiovascular disease, in particular in EMS.

BioSig Technologies, Inc. Adopts Stockholder Rights Agreement

Retrieved on: 
Thursday, July 16, 2020
Medicine, Branches of biology, Clinical medicine, Cardiac electrophysiology, Electrocardiography, Electrodiagnosis, Electrophysiology

BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its Board of Directors had adopted a stockholder Rights Agreement (the Rights Agreement).

Key Points: 
  • BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that its Board of Directors had adopted a stockholder Rights Agreement (the Rights Agreement).
  • The Rights Agreement applies equally to all current and future stockholders.
  • The Rights Agreement has a duration of one year, expiring July 9, 2021, and is similar to those adopted by many other public companies.
  • This announcement is a summary only and is qualified by reference to the full text of the Rights Agreement.

AliveCor Expands Telemedicine Services to Support Heart Care at Home

Retrieved on: 
Thursday, July 9, 2020
Medicine, Articles, Health informatics, Branches of biology, Alivecor, Telehealth, Cardiac electrophysiology, Electrocardiography, Health Insurance Portability and Accountability Act, Regulatory compliance

As a result of the pandemic, healthcare has seen a significant increase in the use of telemedicine among both providers and patients.

Key Points: 
  • As a result of the pandemic, healthcare has seen a significant increase in the use of telemedicine among both providers and patients.
  • Other features include automatic ECG sharing with family and caregivers, a monthly heart health report summarizing heart data over 30 days, and a care plan task list with reminders.
  • AliveCor protects its customers with stringent data security and compliance practices , achieving HIPAA compliance and Type 1 SOC2 attestations.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

The veterinary monitoring equipment market is projected to reach USD 570 million by 2025 from USD 326 million in 2019, at a CAGR of 9.8%

Retrieved on: 
Friday, May 29, 2020
Medicine, Clinical medicine, Medical specialties, Medical tests, Medical monitoring, Intensive care medicine, Monitoring, Nanomedicine, Pulse oximetry, Capnography, Electrocardiography, Vital signs

The veterinary monitoring equipment market is projected to reach USD 570 million by 2025 from USD 326 million in 2019, at a CAGR of 9.8%.

Key Points: 
  • The veterinary monitoring equipment market is projected to reach USD 570 million by 2025 from USD 326 million in 2019, at a CAGR of 9.8%.
  • On the basis of type, the veterinary monitoring equipment market segmented into vital sign monitors, anesthesia monitors, capnography & oximetry systems, ECG & EKG monitors, MRI systems, and other equipment.The vital sign monitors segment is projected to witness the highest growth in the veterinary monitoring equipment market during the forecast period.
  • A breakdown of the primary participants referred to for this report is provided below:
    The prominent players in the veterinary monitoring equipment market are Smiths Group plc.
  • The report analyzes the market for various veterinary monitoring equipment and their adoption patterns.It aims at estimating the market size and future growth potential of the veterinary monitoring equipment market and its subsegments.

Advancements Television Series to Educate About Recent Improvements in Manufacturing and Technology

Retrieved on: 
Thursday, May 28, 2020
Medicine, Branches of biology, Clinical medicine, Design, Innovation, Product management, Electrocardiography, ATI Technologies

JUPITER, Fla., May 28, 2020 /PRNewswire-PRWeb/ -- Advancements with Ted Danson will focus on recent innovations in finishing solutions and manufacturing strategies in an upcoming episode, scheduled to broadcast in the fall of 2020.

Key Points: 
  • JUPITER, Fla., May 28, 2020 /PRNewswire-PRWeb/ -- Advancements with Ted Danson will focus on recent innovations in finishing solutions and manufacturing strategies in an upcoming episode, scheduled to broadcast in the fall of 2020.
  • In this segment, Advancements will focus on Expert Coatings & Graphics (ECG) and will educate about its innovative manufacturing solutions in a wide array of secondary operations including cosmetic, protective and functional coatings, EMI/RFI conductive finishes, graphics application, assembly, warehouse and distribution.
  • In addition, the show will explore how ECG serves an esteemed caliber of global organizations and OEM leaders in the medical, aerospace, defense, and automotive industries.
  • About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.